Shanghai Allist Pharmaceuticals Co., Ltd. Stock
Equities
688578
CNE100005XJ7
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 99.14 CNY | +1.03% |
|
+2.98% | +65.51% |
| 12-08 | Allist Pharmaceuticals' Two Cancer Drugs Placed on China's Insurance Drug List | MT |
| 11-07 | Nomura Starts Shanghai Allist Pharmaceuticals at Buy With 141.56 Yuan Price Target | MT |
| Capitalization | 44.61B 6.32B 5.39B 5.03B 4.73B 8.72B 573B 9.52B 58.74B 22.78B 270B 23.73B 23.23B 985B | P/E ratio 2025 * |
23.2x | P/E ratio 2026 * | 19.8x |
|---|---|---|---|---|---|
| Enterprise value | 44.61B 6.32B 5.39B 5.03B 4.73B 8.72B 573B 9.52B 58.74B 22.78B 270B 23.73B 23.23B 985B | EV / Sales 2025 * |
8.92x | EV / Sales 2026 * | 7.46x |
| Free-Float |
40.99% | Yield 2025 * |
0.4% | Yield 2026 * | 0.46% |
| 1 day | +1.03% | ||
| 1 week | +2.98% | ||
| Current month | +0.86% | ||
| 1 month | -2.38% | ||
| 3 months | -12.87% | ||
| 6 months | +3.26% | ||
| Current year | +65.51% |
| 1 week | 97.12 |  | 100.5 |
| 1 month | 93.21 | | 104 |
| Current year | 57.03 | | 122.2 |
| 1 year | 57.03 | | 122.2 |
| 3 years | 18.15 | | 122.2 |
| 5 years | 14.81 | | 122.2 |
| 10 years | 14.81 | | 122.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jin Hao Du
CEO | Chief Executive Officer | 71 | 2022-09-13 |
Feng Xu
PRN | Corporate Officer/Principal | 60 | 2016-12-31 |
Jie Hu
PRN | Corporate Officer/Principal | 50 | 2020-03-10 |
| Director | Title | Age | Since |
|---|---|---|---|
Jin Hao Du
CHM | Chairman | 71 | 2004-03-21 |
Ju Qi
BRD | Director/Board Member | 73 | 2019-11-27 |
Jie Hu
BRD | Director/Board Member | 50 | 2019-06-24 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.03% | +2.98% | +59.29% | +384.08% | 6.32B | |
| -0.48% | -2.31% | +29.50% | +98.73% | 54.11B | |
| +0.91% | -3.43% | +173.44% | +917.09% | 42.02B | |
| +0.70% | +4.04% | +64.74% | +16.53% | 39.6B | |
| -1.24% | -1.50% | -21.44% | -43.10% | 22.8B | |
| -1.52% | -0.84% | +35.42% | -38.02% | 19.5B | |
| 0.00% | +2.64% | +84.36% | -35.43% | 17.76B | |
| +6.05% | +0.32% | +88.92% | +210.09% | 14.73B | |
| -2.33% | -4.04% | -1.68% | +523.05% | 13.55B | |
| +0.02% | -1.02% | +88.92% | +799.06% | 12.98B | |
| Average | +0.31% | -0.57% | +60.15% | +283.21% | 24.34B | |
| Weighted average by Cap. | +0.19% | -0.89% | +65.59% | +267.74% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 5B 709M 604M 564M 531M 978M 64.24B 1.07B 6.59B 2.56B 30.28B 2.66B 2.61B 110B | 5.98B 848M 722M 675M 635M 1.17B 76.79B 1.28B 7.88B 3.05B 36.2B 3.18B 3.11B 132B |
| Net income | 1.93B 273M 233M 217M 204M 376M 24.72B 411M 2.54B 983M 11.65B 1.02B 1B 42.52B | 2.25B 319M 272M 254M 239M 439M 28.88B 480M 2.96B 1.15B 13.61B 1.2B 1.17B 49.66B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-12 | 99.14 ¥ | +1.03% | 7,241,905 |
| 25-12-11 | 98.13 ¥ | -1.01% | 2,556,417 |
| 25-12-10 | 99.13 ¥ | +0.64% | 2,461,746 |
| 25-12-09 | 98.50 ¥ | +1.13% | 2,934,109 |
| 25-12-08 | 97.40 ¥ | +1.17% | 2,732,058 |
End-of-day quote Shanghai S.E., December 11, 2025
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Annual profits - Rate of surprise
- Stock Market
- Equities
- 688578 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition